GENEART wins "European Biotechnica Award"

The British company Astex Therapeutics Limited and the German company immatics biotechnologies GmbH were honoured as finalists

09-Oct-2008 - Germany

GENEART AG, a leader in gene synthesis and specialist in the field of synthetic biology was awarded the "European Biotechnica Award" during the ceremonial opening of "Biotechnica 2008". The prize was presented by the Vice President of the European Commission, Günter Verheugen. The award comprises of a total of EUR 100,000 and honours innovative European companies with powerful business concepts in the areas of biotechnology and life sciences. The winner receives EUR 20,000 in cash and considerable non-cash benefits. In addition to GENEART, the companies Astex Therapeutics Limited and immatics biotechnologies GmbH also reached the final. The prize was awarded for the sixth time by the Deutsche Messe and its partners. Since its market entrance in 2000, GENEART has revolutionized the gene synthesis and lifted the production of gene sequences from a manual lab process to a highly industrialized level. Thereby GENEART provided researchers from industry and science a cost effective and fast access to gene sequences. By now, for instance, pharmaceutical companies profit from this in their development of drugs and vaccines. GENEART is one of the few biotech companies in Germany, which sustainably does not only generate sales but also profits. "We are pleased that our work is validated by the prestigious "European Biotechnica Award". This award emphasizes GENEART's successful advancement since its foundation, and the value of our technology for development in red, white and green biotechnology", stated Prof. Dr. Ralf Wagner, CEO of GENEART AG.

https://www.analytica-world.com/en/news/87990/geneart-wins-european-biotechnica-award.html